


LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637(BOT)	SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R.	TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: 12/9/03	GROUP: 1645



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
<i>AA</i>	AA	10,184,805		Donovan, Stephen			7/11/2002
	AB	5,437,291	8/1/1995	Pasricha et al.			
	AC	5,670,484	9/23/1997	Binder, William			
	AD	5,714,468	2/3/1998	Binder, William			
	AE	5,766,605	6/16/1998	Sanders et al.			
	AF	5,989,545	11/23/1999	Foster et al.			
	AG	6,063,768	5/16/2000	First, Eric			
	AH	6,139,845	10/31/2000	Donovan, Stephen			
	AI	6,265,379	7/24/2001	Donovan, Stephen			
	AJ	6,299,893	10/9/2001	Schwartz et al.			
	AK	6,306,423	10/23/2001	Donovan et al.			
	AL	6,312,708	11/6/2001	Donovan, Stephen			
	AM	6,358,926	3/19/2002	Donovan, Stephen			
	AN	6,423,319	7/23/2002	Brooks et al.			
	AO	6,458,365	10/1/2002	Aoki et al.			
	AP	6,464,986	10/15/2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

<i>CA</i>	CA	Andreadis S., et al., <i>Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system</i> , FASEB J. 2001 Apr;15(6):898-906
<i>CB</i>	CB	Aoki K., et al, <i>Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing</i> , Cephalalgia 2003 Sep;23(7):649

EXAMINER

Laker


DATE CONSIDERED

8/20/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637(BOT)	SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R.	TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: 12/9/03	GROUP: 1645



L2	CC	Arredondo J., et al., <i>Central role of alpha7 nicotinic receptor in differentiation of the stratified squamous epithelium</i> , J Cell Biol. 2002 Oct 28;159(2):325-36
	CD	Asahina A., et al., <i>Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects</i> , Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8323-7
	CE	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
	CF	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
	CG	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16);9153-9158:1990
L2	CH	Brem, H., et al, <i>Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas</i> , Lancet 345;1008-1012:1995
	CI	Bushara K., Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507
L2	CJ	Chen W., et al., <i>Trophic interactions between sensory nerves and their targets</i> , Journal of Biomedical Science. 1999;6(2):79-85
	CK	Chiang H-Y, et al., Regional difference in epidermal thinning after skin denervation, Exp Neurol 1998;154(1):137-45
L2	CL	Chien., et al., (2001) <i>Quantitative pathology of cutaneous nerve terminal degeneration in the human skin</i> , Acta Neuropathologica 102:455-461
	CM	Duggan et al.; A survey of Botulinum neurotoxin substrate expression in cells; Mov Disord, 10(3):376:1995
L2	CN	Fung L. K. et al., <i>Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain</i> , Cancer Research 58;672-684:1998
	CO	Gonelle-Gispert et al.; <i>Snap -25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion</i> ; Biochem -J 1;339 (pt 1):159-65:1999
L2	CP	Grando S., <i>Biological functions of keratinocyte cholinergic receptors</i> , J Investig Dermatol Symp Proc. 1997 Aug;2(1):41-8

EXAMINER

Lakia [Signature]

DATE CONSIDERED

8/20/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637(BOT)	SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R.	TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: 12/9/03	GROUP: 1645


L2	CQ	Grando S., et al., <i>Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation</i> . Invest Dermatol. 1996
	CR	Grando S., et al., <i>Human keratinocytes synthesize, secrete, and degrade acetylcholine</i> J Invest Dermatol. 1993 Jul;101(1):32-6
	CS	Grando S., et al., <i>Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization</i> , J Invest Dermatol. 1995 Jan;104(1):95-100
	CT	Griffin J., et al., <i>Axonal degeneration and disorders of the axonal cytoskeleton</i> . In: Waxman S., et al., <i>The Axon</i> . New York: Oxford University Press, 1995:375-390
	CU	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2):522-527:1988)
	CV	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate</i> , Experientia 44:224-226:1988
L2	CW	Habermann, E.; <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56
	CX	<i>Harrison's Principles of Internal Medicine</i> (1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill
	CY	Hokfelt T., <i>Neuropeptides in perspective : The last ten years</i> , Neuron 1991; 7: 867-879
	CZ	Hosoi J., et al., <i>Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide</i> , Nature. 1993 May 13;363(6425):159-63
	CAA	Hsieh S., et al., <i>Epidermal denervation and its effects on keratinocytes and Langerhans cells</i> , J Neurocytol. 1996 Sep;25(9):513-24
	CBB	Hsieh S., et al., <i>Modulation of keratinocyte proliferation by skin innervation</i> . Journal of Investigative Dermatology, 1999;113(4):579-86
	CCC	Hsieh S., et al., <i>Pathology of nerve terminal degeneration in the skin</i> , Journal of Neuropathology & Experimental Neurology. 2000;59(4):297-307
	CDD	Hsieh S., et al., <i>Skin Innervation and Its Effects on the Epidermis</i> , J Biomed Sci. 1997;4(5):264-268
L2	CEE	Huang et al.; <i>Influence of Cutaneous Nerves on Keratinocyte Proliferation and Epidermal Thickness in Mice</i> ; Neuroscience. 1999;94(3):965-73



EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637(BOT)		SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R.		TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: 12/9/03		GROUP: 1645

	CFF	Inaba N., et al., <i>Capsaicin-induced calcitonin gene-related peptide release from isolated rat stomach measured with a new chemiluminescent enzyme immunoassay</i> , Jpn J Pharmacol. 1996 Nov;72(3):223-9
	CGG	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page 5, 150
	CHH	Johnson M., <i>Synaptic glutamate release by postnatal rat serotonergic neurons in microculture</i> , Neuron 1994; 12: 433-442
	CII	Kaneko T., et al., <i>Immunohistochemical demonstration of glutaminase in catecholaminergic and serotonergic neurons of rat brain</i> , Brain Res. 1990; 507: 141-154
	CJJ	Kasakov L., et al., <i>Direct evidence for concomitant release of noradrenaline, adenosine 5'-triphosphate and neuropeptide Y from sympathetic nerve supplying the guinea-pig vas deferens</i> . J. Auton. Nerv. Syst. 1988; 22: 75-82
	CKK	Katsambas A., et al., <i>Cutaneous diseases of the foot: Unapproved treatments</i> , Clin Dermatol 2002 Nov-Dec;20(6):689-699
	CLL	Ko M., et al., <i>Cutaneous nerve degeneration induced by acrylamide in mice</i> , Neuroscience Letters. (2000)293(3):195-8
	CMM	Komuves et al., <i>Epidermal Expression of the Full-Length Extracellular Calcium-sensing Receptor is Required for Normal Keratinocyte Differentiation</i> ; J Cell Physiol. 2002 Jul;192(1):45-54
	CNN	Krnjevic K., <i>Central cholinergic mechanisms and function</i> . Prog Brain Res. 1993;98:285-92
	COO	Kupfermann I.; <i>Functional studies of cotransmission</i> . Physiol. Rev. 1991; 71: 683-732.48: 545-59
	CPP	Lee M., et al., <i>Clinical and electrophysiological characteristics of inflammatory demyelinating neuropathies</i> , Acta Neurol Taiwan 1997;6:283-288
	CQQ	Legat F., et al., <i>Repeated subinflammatory ultraviolet B irradiation increases substance P and calcitonin gene-related peptide content and augments mustard oil-induced neurogenic inflammation in the skin of rats</i> , Neurosci Lett. 2002 Sep 6;329(3):309-13
	CRR	Li Y., et al., <i>Sensory and motor denervation influences epidermal thickness in rat foot glabrous skin</i> , Exp Neurol 1997;147:452-462 (see page 459)
	CSS	Lin Y., et al., (2001) <i>Cutaneous nerve terminal degeneration in painful mononeuropathy</i> , Experimental Neurology. 170(2):290-6


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637(BOT)	SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R	TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: 12/9/03	GROUP: 1645



CTT	Lin Y., et al., <i>Quantitative sensory testing: normative values and its application in diabetic neuropathy</i> , Acta Neurol Taiwan 1998;7:176-184
CUU	Lundberg J., <i>Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide</i> , Pharmacol. Rev. 1996; 48: 113-178
CVV	McCarthy B., et al., <i>Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy</i> , Neurol 1995;45:1848-1855
CWW	Moyer E et al., <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
CXX	Naumann et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> ; European J. Neurology 6 (Supp 4): S111-S1150:1999
CYY	Ndoye A., et al., <i>Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis</i> , J Invest Dermatol. 1998 Sep;111(3):410-6
CZZ	Nguyen V., et al., <i>Keratinocyte acetylcholine receptors regulate cell adhesion</i> ; Life Sci. 2003 Mar 28;72(18-19):2081-5
CAAA	Nguyen V., et al., <i>Programmed cell death of keratinocytes culminates in apoptotic secretion of a humectant upon secretagogue action of acetylcholine</i> J Cell Sci. 2001 Mar;114(Pt 6):1189-204
CBBB	Nicholas A. et al., <i>Glutamate-like immunoreactivity in medulla oblongata catecholamine/substance P neurons</i> , NeuroReport 1990; 1: 235-238
CCCC	Palacios J., et al., <i>Cholinergic neuropharmacology: an update</i> , Acta Psychiatr Scand Suppl. 1991;366:27-33
CDDD	Pan C., et al., (2001) <i>Degeneration of nociceptive nerve terminals in human peripheral neuropathy</i> , Neuroreport. 12(4):787-92
CEEE	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon 35(9);1373-1412 at 1393
CFFF	Ragona et al., <i>Management of Parotid Sialoceles With Botulinum Toxin</i> ; The Laryngoscope 109:1344-1346:1999
CGGG	Rogers J., et al., <i>Injections of botulinum toxin A in foot dystonia</i> , Neurology 1993 Apr;43(4 Suppl 2
CHHH	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem 165;675-681:1997



EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17637(BOT)	SERIAL NO.: 10/731,973
APPLICANT: FIRST, ERIC R.	TITLE: BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS
FILING DATE: 12/9/03	GROUP: 1645

	CIII	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56;80-99:1992
	CJJJ	Sevim, S., et al., <i>Botulinum toxin-A therapy for palmar and plantar hyperhidrosis</i> , Acta Neurol Belg 2002 Dec;102(4):167-70
	CKKK	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976)
	CLLL	Sloop et al.; <i>Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> ; Neurology, 48:249-53:1997
	CMMM	Sneddon P., et al., <i>Pharmacological evidence that adenosine triphosphate and noradrenaline are cotransmitters in the guinea-pig vas deferens</i> . J. Physiol. 1984; 347: 561-580
	CNNN	Suputtitada, A., <i>Local botulinum toxin type A injections in the treatment of spastic toes</i> , Am J Phys Med Rehabil 2002 Oct;81(10):770-5
	COOO	Tacks, L., et al., <i>Idiopathic toe walking: Treatment with botulinum toxin A injection</i> , Dev Med Child Neurol 2002;44(Suppl 91):6
	CPPP	Whitehouse P., et al., <i>Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders</i> , J Neural Transm Suppl. 1987;24:175-82
	CQQQ	Wiegand et al, <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> ; Nauny-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165
	CRRR	Wu T., et al., <i>Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice</i> , J Virol Methods 1997;65:287-298
	CSSS	Xu Z-QD et al, <i>Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and - R2 receptors</i> , J. Comp. Neurol. 1998; 392: 227-252
	CTTT	Xu Z-QD et al, <i>Galanin-5-hydroxytryptamine interactions: Electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors</i> . Neuroscience 1998; 87: 79-94;
	CUUU	Zia S., et al., <i>Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration</i> , J Pharmacol Exp Ther. 2000 Jun; 293(3):973-81

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.